Funded Biomarker Testing
1 items
Testing on previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) where FGFR2 directed therapy is being considered
Funded Biomarker Disease Site: Hepatobiliary
Biomarker: FGFR2
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Hospital for Sick Children (SickKids), London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System